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Abstract
Background—Hepatitis E virus (HEV) infection has become relevant to blood transfusion 
practice because isolated cases of blood transmission have been reported and because HEV has 
been found to cause chronic infection and severe liver disease in immuno-compromised patients.
Study design and Methods—We tested for IgG and IgM antibodies to the hepatitis E virus 
(HEV) and for HEV RNA in 1939 unselected volunteer US blood donors. Subsequently, we tested 
the same parameters in pre- and serial post-transfusion samples from 362 prospectively followed 
blood recipients to assess transfusion risk.
Results—IgG anti-HEV seroprevalence in the total 1939 donations was 18.8%: 916 of these 
donations were made in 2006 at which time the seroprevalence was 21.8% and the remaining 1023 
donations were in 2012 when the seroprevalence had decreased to 16.0% (p<0.01). A significant 
(P<0.001) stepwise increase in anti-HEV seroprevalence was seen with increasing age. Eight of 
1939 donations (0.4%) tested anti-HEV IgM positive; no donation was HEV RNA positive. Two 
recipients had an apparent anti-HEV seroconversion, but temporal relationships and linked donor 
testing showed that these were not transfusion transmitted HEV infections.
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Conclusion—No transfusion-transmitted HEV infections were observed in 362 prospectively 
followed blood recipients despite an anti-HEV seroprevalence among donations exceeding 16%.
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Introduction
Hepatitis E virus (HEV) infection has been recognized as an important cause of acute, often 
epidemic, hepatitis in Asia and was believed to be rare in industrialized countries.1,2 
However, indigenous HEV infections are increasingly reported in developed nations, and 
most are caused by HEV genotypes 3 or 4 as compared to genotypes 1 and 2 that are 
associated with large outbreaks due to contaminated water supplies.3,4 In addition, HEV 
seroprevalence among blood donors and the general population in industrialized countries 
has been found to be much higher than expected and accumulating evidence suggests that 
the clinical importance of HEV infection in non-endemic regions has been 
underestimated. 5–7 The routes of transmission in countries with safe water supplies are not 
well defined, though transmission from contaminated pork products has been demonstrated 
in southwestern France and other regions.5,8–10
The high seroprevalence of infection in asymptomatic individuals raises the potential risk of 
HEV transmission through blood transfusion. Though such transmission appears to be rare, 
a small number of transfusions related cases have been reported and confirmed by molecular 
identity of the agent in donor and recipient.11–13 Importantly, this infection, once thought to 
be universally self-limiting, has now been shown to result in chronic infection and cirrhosis 
in immune-compromised patients and to exacerbate fibrosis progression and liver-related 
mortality in infected subjects with pre-existing liver disease.13–15 The potential risk of blood 
transmission is compounded by the high proportion of blood recipients who are 
immunosuppressed and repeatedly transfused.
In United States, HEV seroprevalence was found to be 21% in a national health survey 
(NHANES III) conducted from 1988 to 1994 16 and then to have fallen to 6.4 % in a similar 
survey (NHANES IV) conducted by the Centers for Disease Control from 2009 to 201017. 
The reason for the fall in HEV seroprevalence between these two surveys is currently 
unexplained. To better assess the risk of HEV transmission by blood transfusion we 
investigated HEV seroprevalence among healthy US blood donors and tracked transmission 
rates among blood recipients enrolled in an ongoing prospective study of transfusion 
transmitted infections (TRIPS). We utilized a commercial anti-HEV assay that performed 
well in comparative studies18 and a sensitive in-house PCR assay validated with plasma 
from persons confirmed to have HEV genotype 3 infection.
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In our study, all tests were performed on plasma samples. In the donor study, we used 
unselected NIH volunteer blood donor samples obtained in two different time periods, 
specifically 2006 and 2012. In the recipient study, samples were tested pre-transfusion and 
then at 4 and/or 8 weeks post-transfusion, and at the end of the study (ES, 24 or 36 weeks 
post-transfusion): 21% of recipients had a pre-sample and 3 post-transfusion samples and all 
recipients had a pre-sample and at least one sample obtained 8 or more weeks after 
transfusion. Linked donor samples were available for most recipients. Donor samples used 
for determination of HEV seroprevalence were not linked to specific recipients.
The TRIPS repository was initiated in November 2001 and is composed of linked donor-
recipient specimens from transfusion recipients enrolled at the NIH Clinical Center 
(Bethesda, MD) and the Children’s National Medical Center (Washington, DC) and from 
Suburban Hospital (Bethesda, MD). Informed consent was obtained from all donors and 
recipients in accordance with the Declaration of Helsinki for participation in NIH-sponsored 
and institutional review board–approved protocols (NIH Protocol 01-CC-0231; Children’s 
National Medical Center, Protocol 2540). Human subjects were assigned a code number, 
and all TRIPS patient samples and both linked and unlinked donor samples were identified 
only by that code; the testing laboratories had no capability of linking the code number to 
the study participant’s name.
Anti-HEV serology
Anti-HEV IgG and IgM antibodies were detected by ELISA using assays manufactured by 
Wantai Pharmaceutical Co., Beijing, China (Research use only). This assay utilizes a 
recombinant peptide corresponding to open reading frame 2 (ORF2) of the HEV genome.19 
According to the package insert, this assay has a specificity of 98.6% in testing 9012 healthy 
Asian subjects. It is to be noted that confirmatory assays for HEV IgM and IgG antibodies 
are not available rendering positive findings only presumptive. Testing was performed 
according to the manufacturer’s instructions. Briefly, samples were diluted 1:10, added to 
antigen coated plates and incubated for 30 minutes. Then HRP-conjugate was added and 
followed by another 30 minutes incubation. After incubation, color development was 
measured at an absorbance of 450nm. Results were calculated as sample/cutoff ratios: values 
of 1.0 or above were considered reactive. Each sample was tested in duplicate and all 
positive samples were confirmed in a repeat duplicate assay. Only samples reactive in at 
least 3 of the 4 quadruplicate assays were considered positive.
HEV RNA detection
Pools of 7–8 donor samples were tested for HEV RNA by both Real-time RT PCR20 and a 
nested PCR 21. The 95% limit of detection (LOD) for the real time PCR assay was 400 
IU/mL and the 50% LOD was 200 IU/mL. For the nested PCR, the 95% LOD was 200 
IU/mL and the 50% LOD was 50 IU/mL. IgM positive samples were tested individually by 
both PCR methods. Nucleic acid isolation was performed using the QIAamp Viral RNA 
Mini kit (Qiagen) according to the manufacturer’s instructions. For Real-time PCR, highly 
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conserved sequences in the open reading frame (ORF) 3 region of all HEV genotypes were 
targeted: forward primer (JVHEVF; 5′-GGTGGTTTCTGGGGTGAC-3′), reverse primer 
(JVHEVR: 5′-AGGGGTTGGTTGGATGAA-3′) and probe (JVHEVP: FAM-5′-
TGATTCTCAGCCCTTCGC-3′-TAMRA). For nested PCR, a 150-nt segment of ORF2, 
was amplified with primers E1 (5′-CTGTTTAAYCTTGCTGA CAC- 3′) and E5 (5′-
WGARAGCCAAAGCACATC-3′ ′ ′) in the first round of PCR and primers E2 (5′-
GACAGAATTGATTTCGTCG-3′) and E4 (5′-TGYTGGTTRTCRTAATCCTG-3′) in the 
second round. PCR cycling conditions for both rounds consisted of 35 cycles of denaturation 
at 94°C for 30 s, annealing at 53°C for 30 s, and extension at72°C for 40 s. A positive HEV 
RNA control (200 IU/ml) was included in each assay.
Statistical methods




General characteristics of the 1939 blood donations examined are summarized in Table 1. 
The first 916 samples were collected from 01/03/2006 to 05/19/2006. The remaining 1023 
donations were collected from 01/03/2012 to 03/21/2012. HEV IgG was detected in 364 
(18.8%) of the total 1939 blood donations (95% confidence interval [CI], 17.0%–20.5%). 
The ranges of sample/cutoff ratios for positive and negative samples showed a clear bimodal 
distribution (Fig. 1). The mean ± SD sample/cutoff ratio of the positive samples was 8.15 ± 
5.06. The seroprevalence was 21.8% (95% confidence interval [CI], 19.2%–24.5%) in year 
2006 samples and 16.0% (95% confidence interval [CI], 13.8%–18.3%) in year 2012 
samples (P<0.01).
We analyzed three demographic variables for their association with IgG seroprevalence 
using the samples obtained in 2006. No statistically significant association was found in 
regard to gender or race (data not shown). There was a strong statistical association with age 
(P<0.001): the seroprevalence of anti-HEV IgG was 3.4% (95% confidence interval [CI], 
0.7% – 6.0%) in ages below 25, and then increased linearly to 42.2% (95% confidence 
interval [CI], 31.8% – 52.6%) in those over age 65 (Fig. 2). Age data were not available for 
samples obtained in 2012.
There were 8 donations that tested anti-HEV IgM reactive among the 1939 donations 
(0.4%). HEV RNA was not detected in any donations.
RECIPIENT TESTING
The anti-HEV IgG seroprevalence of the 362 recipients in their pre-transfusion samples was 
21.5% (95% confidence interval [CI], 17.3% – 25.8%) and thus very similar to the blood 
donor population. One recipient (0.3%) was IgM anti-HEV positive in the pre-transfusion 
sample, but no recipient was IgM anti-HEV positive in any post-transfusion sample.
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Among the 362 recipients there were two instances (0.6%) where the last post-transfusion 
sample was anti-HEV positive while the pre-transfusion sample was anti-HEV negative. 
These potential anti-HEV seroconversions were further investigated. In recipient 1, we 
tested all available samples from the time of transfusion to the end of study sample that 
tested anti-HEV positive. Each of these interim samples, obtained at 4, 12 and 20 weeks 
post-transfusion, tested negative for anti-HEV IgM and IgG and for HEV RNA (Fig. 3). 
Thus, the finding of anti-HEV in the late post-transfusion sample was an isolated, albeit 
reproducible finding. Next we tested linked donations: such samples were available for 69 of 
the 72 blood products received by this patient during the course of the study. In the 69 
linked donations tested, the anti-HEV IgG seroprevalence was 14.5% (95% confidence 
interval [CI], 6.0% – 23.0%). One of IgG positive donations was also anti-HEV IgM 
reactive. Four days before the recipient sample that tested anti-HEV IgG positive, this 
repeatedly transfused patient received blood from a donation which was HEV RNA positive 
by nested PCR and from a second donation which had high titer anti-HEV antibody (sample/
cutoff ratio > 20). Since the interval from transfusion of these HEV reactive blood donations 
to the detection of HEV antibody in the recipient was only four days, we conclude that IgG 
antibody detected in the patient was passively transferred from the donated unit with high 
titer anti-HEV and hence did not indicate a true seroconversion or a transfusion associated 
HEV infection. Unfortunately, the patient died soon after receipt of the HEV RNA positive 
blood donation so that we could not trace whether that blood unit would have transmitted 
HEV infection.
In the potential anti-HEV seroconversion recipient 2, all post-transfusion samples showed 
low level anti-HEV reactivity with sample/cutoff ratios gradually increasing from 1.5 at 
week 4 to 2.5 at week 24 post-transfusion (Fig. 3). Neither IgM anti-HEV nor HEV RNA 
was detected in any post-transfusion sample. Although the pre-transfusion sample was 
below the assay cut-off and thus interpreted as negative, in retrospect it was just below the 
cut-off and probably the onset of an anti-HEV antibody response that preceded study 
enrollment. The cause of this HEV antibody response is unknown, but we conclude it was 
not related to the index transfusion in this study. None of the linked donations tested in this 
case had HEV markers, but we only had access to 2 of 5 donations to this patient.
These two cases illustrate the importance of having serial recipient samples and linked 
donations in interpreting apparent recipient seroconversion after blood transfusion. In sum, 
we did not observe any cases of transfusion-transmitted HEV infection among 362 
prospectively followed blood recipients despite the high seroprevalence of anti-HEV IgG in 
our population. The observation of zero HEV infections among 362 recipients could 
represent a true infection rate up to 0.8% based on the upper bound of the 95% confidence 
interval according to the “rule of 3”.22,23
Discussion
The results of our study show an anti-HEV IgG seroprevalence approaching 19% in testing 
1939 blood donations. This proportion is similar to previous studies16 and confirms that 
exposure to HEV is common in the US blood donor population. Although the 
seroprevalence appears to have decreased over the 6-year interval between 2006 and 2012, 
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evidence of recent or past HEV exposure remains very high. In general population surveys 
conducted by CDC (National Health and Nutrition Survey, NHANES), a more striking 
decline in anti-HEV seroprevalence was observed between 1988–1994 and 2009–2010 with 
a fall from 21% to 6%.16,17 Continued monitoring of HEV seroprevalence will be important 
to elucidate the root causes of transmission.
Estimates of HEV seroprevalence are highly dependent on assay sensitivity and more 
recently employed assays appear to be both more sensitive and specific. The anti-HEV assay 
utilized in this study was manufactured by Wantai Pharmaceutical Co. and is now widely 
used in Asia and Europe where its enhanced sensitivity has resulted in large increases in 
anti-HEV seroprevalence as compared with earlier assays.5,18,24–26 The difference between 
the HEV seroprevalence observed in our study of blood donors in 2012 (16%) compared to 
the NHANES IV population survey in 2009–2010 (6%) may in part reflect test sensitivity 
rather than true differences in seroprevalence in the tested populations. Although 
preliminary studies indicate that the increased sensitivity of the Wantai assay does not come 
at the expense diminished specificity, there is great need to develop HEV standards and 
pedigreed panels to allow valid comparisons among the competing assays to determine 
whether differences in seroprevalence are geographic or epidemiologic or simply assay 
dependent. Such panels are now under development.
No HEV viremia was detected in the approximate 2000 donations tested in this study, but 
this number of donations is too small to detect a low occurrence event and much larger 
surveys are needed. We did, however find a small percentage of donations with IgM 
reactivity suggesting recent infection and posing the potential for relevant incident infections 
in the donor population. Indeed, although we did not find an HEV RNA positive donation in 
the donor testing phase of this study, we did find an HEV RNA positive donation when 
retrospectively testing linked donations to a case of potential transfusion-associated anti-
HEV seroconversion. These indications of recent HEV infections in blood donors indicate 
the need for continued vigilance for HEV in the blood supply and the need for recipient 
tracing through prospective studies and look-back investigations. In our study, as in 
others5,16, advancing age is a key correlate of anti-HEV seroprevalence. It is probable that 
this represents cumulative exposure over time, but an alternate explanation is that there is a 
cohort effect wherein the population had an unidentified, non-lethal HEV exposure in the 
remote past and the resulting antibody response has been carried forward into old age.
Sporadic cases of transfusion related HEV infection have been reported recently11–13 and 
have been confirmed by molecular linkage between donor and recipient. Thus, the issue at 
hand is not whether HEV can be transmitted by transfusion, but rather how often and with 
what consequences?
In the prospective arm of our study, we tested pre- and post-transfusion samples from 362 
recipients. The HEV seroprevalence of the recipients before transfusion was very similar to 
that of the blood donors we tested suggesting that HEV exposure and infection is 
widespread in the US population. Most recipients in our study received blood from at least 5 
donations enhancing the possibility that a patient would receive blood from a donor 
previously infected with HEV. Based on the average transfusion number and the 0.4% 
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seroprevalence of IgM anti-HEV, recipients in this study would have had a 1%–2% chance 
of receiving blood from recently infected, IgM positive blood donor.
Two recipients (0.6%) among the 362 total recipients prospectively followed had an 
apparent anti-HEV IgG seroconversion suggesting transfusion-transmitted HEV infection. 
However, in one of these recipients, IgG anti-HEV was detected in only the last study 
sample at 36 weeks after his first within-study transfusion. No IgM antibody or HEV RNA 
was detected in post-transfusion samples obtained prior to the appearance of IgG anti-HEV. 
Investigation of linked donations to this repeatedly transfused recipient revealed that the 
patient was transfused with a strongly reactive anti-HEV positive donation just prior to the 
detection of anti-HEV in his last follow-up sample. Thus, the antibody detected in this 
recipient was passively transferred and not indicative of HEV infection followed by anti-
HEV seroconversion. Interestingly, the patient also received an HEV RNA positive and an 
IgM anti-HEV positive blood unit four days before our last study sample. The patient died 
soon thereafter and thus we could not trace the outcome of HEV positive blood donations. 
However, this does demonstrate that HEV RNA positive donors exist in our donor 
population even though none were detected in the approximate 2000 donations tested in the 
donor sero-survey.
In the second recipient demonstrating suspected seroconversion, retrospective testing 
revealed that all his post-transfusion samples were weakly reactive for anti-HEV beginning 
with the 4 week post-transfusion sample (Fig. 3). No sample was IgM anti-HEV or HEV 
RNA positive. Linked donations did not reveal an HEV infected donor, but some donations 
were not available for testing. Further examination of this patient’s pre-transfusion sample 
showed that although it fell below the cut-off of the assay and hence was interpreted as anti-
HEV negative, in fact, the OD reading was just below the cut-off and might have 
represented the onset of anti-HEV seroconversion which then increased incrementally 
throughout follow-up. This scenario is compatible with an HEV exposure that occurred prior 
to the index transfusion in this study. We conclude from these two cases that neither patient 
was HEV infected as the result of blood transfusion administered within the time frame of 
the study. More importantly, we conclude that in the proper interpretation of apparent 
antibody seroconversions, it is vital to examine serial recipient samples and to have linked 
donor samples. Access to such samples is only possible in a prospective study design.
Overall, this study concludes that past exposure to HEV is common in the US donor 
population, that a small proportion of such donors have IgM antibody suggestive of recent 
exposure and that a very small proportion harbor HEV RNA. Thus, the potential for 
transfusion-transmitted HEV infection clearly exists and indeed has been confirmed in 
several case reports.11–13 Therefore the issue at hand is not whether HEV can be transmitted 
by transfusion, but rather whether the frequency of such transmission and the clinical 
consequences of the infection warrant donor screening for this agent? HEV fulfills the 
essential criteria for an agent that might justify blood donor screening in that it can be found 
in asymptomatic individuals, it has been proven to be transmitted by transfusion and it can 
cause significant disease in immuno-compromised patients who now constitute a large 
segment of hospitalized blood recipients. What we do not know is the magnitude of the 
problem and the likelihood that an asymptomatic HEV carrier would present to a donor 
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center and be otherwise eligible to donate. Although prolonged asymptomatic viremia has 
been observed in immuno-compromised individuals, it has not been documented in healthy 
blood donors. We know from studies of other blood transmitted agents that it is the duration 
of asymptomatic viremia that best defines the transfusion risk. Agents such as hepatitis A 
virus that have an extremely brief duration of asymptomatic viremia pose little risk whereas 
HBV and HCV, which have prolonged periods of asymptomatic viremia, pose major threats 
and necessitate donor screening by both serology and nucleic acid testing.
Although we did not detect any transfusion associated HEV infections among 362 
prospectively followed recipients in our study, calculation of the upward bound for zero 
observations indicates that HEV transmission could have occurred in up to 0.8% of 
recipients. Further, the finding of IgM anti-HEV in the absence of HEV RNA in 0.4% of 
donors, allows for the possibility that these donors could have been infectious had they 
donated days to weeks earlier when they might have been HEV RNA positive. In addition, 
although we did not find an HEV RNA positive donor in a sero-survey of 1939 donors, we 
did detect one HEV RNA positive donor during investigation of an apparent anti-HEV 
seroconversion in a recipient. Thus, it is probable that HEV positive US blood donors will 
be detected when much larger sero-surveys are performed. The most immediate need for the 
study of HEV and blood transfusion is to test tens of thousands of donors for HEV RNA and 
then to follow those found positive to determine the duration of viremia. If few RNA 
positive donors are identified, as in our study, and if the duration of viremia in immune-
competent individuals is very short, then routine donor screening will not be necessary. In 
contrast, if the occurrence of viremia is frequent and the duration of viremia prolonged, then 
donor screening would be indicated since the disease consequences in those recipients who 
are immune-suppressed and in those with pre-existing liver diseases can be dire.
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Distribution of sample/cut off ratios for hepatitis E virus IgG in positive and negative 
samples from 1939 NIH volunteer blood donors.
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Prevalence of anti-hepatitis E virus (HEV) IgG in 916 NIH volunteer blood donors by age 
group.
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Figure 3. Suspected, but unconfirmed anti-HEV IgG seroconversion in two blood recipients
Recipient 1 received one HEV RNA+ and one high titer anti-HEV IgG+ blood unit 4 days 
before the sample collected at 36 weeks after the index study transfusion. The patient died 
shortly after receiving the HEV RNA+ unit and thus the consequences of that transfusion 
could not be assessed.
Recipient 2 could be interpreted as having a very early seroconversion post-transfusion, but 
more likely was infected prior to the index transfusion based on the timing and on the pre-
transfusion sample having a relatively high, albeit below cut-off.
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Table 1
Hepatitis E markers in NIH volunteer blood donors.
Collection Year No. Tested Anti-HEV IgG+ Anti-HEV IgM+ HEV RNA+
2006 916 200 (21.8%)95% CI: 19.2%–24.5%
3 (0.3%)
95% CI: −0.0%–0.7% 0 (0%)
2012 1023 164 (16.0%)95% CI: 13.8%–18.3%
5 (0.5%)
95% CI: −0.0%–0.9% 0 (0%)
Total 1939 364 (18.8%)95% CI: 17.0%–20.5%
8 (0.4%)
95% CI: 0.1%–0.7% 0 (0%)
*
CI: confidence interval.
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